A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Merck Sharp & Dohme LLC
Cantargia AB
Gilead Sciences
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
BioNTech SE
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Hoffmann-La Roche
Gilead Sciences
Merck Sharp & Dohme LLC
ProDa BioTech, LLC
Cyteir Therapeutics, Inc.
Merck Sharp & Dohme LLC
Cantargia AB
G1 Therapeutics, Inc.
Novartis
OncoSec Medical Incorporated
SynCore Biotechnology Co., Ltd.
Gossamer Bio Inc.
ERYtech Pharma
Bayer
G1 Therapeutics, Inc.
Merck Sharp & Dohme LLC
AstraZeneca
Celgene
Celgene
Sanofi
Piramal Enterprises Limited
Sanofi
Sanofi